EMD-7910

Single-particle
19.0 Å
EMD-7910 Deposition: 23/05/2018
Map released: 25/07/2018
Last modified: 22/08/2018
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-7910

VIC167 Fab in complex with Ebola virus GP

EMD-7910

Single-particle
19.0 Å
EMD-7910 Deposition: 23/05/2018
Map released: 25/07/2018
Last modified: 22/08/2018
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Ebola virus - Mayinga, Zaire, 1976
Sample: Complex of VIC167 Fab bound to Ebola virus GP

Deposition Authors: Turner H, Murin CD, Pallesen J, Ward AB
Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.
PUBMED: 30096313
DOI: doi:10.1016/j.cell.2018.07.033
ISSN: 1097-4172
Abstract:
Antibodies are promising post-exposure therapies against emerging viruses, but which antibody features and in vitro assays best forecast protection are unclear. Our international consortium systematically evaluated antibodies against Ebola virus (EBOV) using multidisciplinary assays. For each antibody, we evaluated epitopes recognized on the viral surface glycoprotein (GP) and secreted glycoprotein (sGP), readouts of multiple neutralization assays, fraction of virions left un-neutralized, glycan structures, phagocytic and natural killer cell functions elicited, and in vivo protection in a mouse challenge model. Neutralization and induction of multiple immune effector functions (IEFs) correlated most strongly with protection. Neutralization predominantly occurred via epitopes maintained on endosomally cleaved GP, whereas maximal IEF mapped to epitopes farthest from the viral membrane. Unexpectedly, sGP cross-reactivity did not significantly influence in vivo protection. This comprehensive dataset provides a rubric to evaluate novel antibodies and vaccine responses and a roadmap for therapeutic development for EBOV and related viruses.